GRAIL is trading 4.13% down at $120.04, with no new company-specific catalyst identified for September 25, 2026. - On September 23, FDA advisers supported Galleri’s benefit-risk profile 7–2, with one abstention; effectiveness passed 6–4. - The broader market is modestly higher, so macro sentiment does not clearly explain GRAIL’s decline.